This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Evotec Reports Full-Year 2010 Results: A Good Year With A Strong Start Into 2011

As a consequence of executing on this strategy, the Company's clinical development expenses decreased significantly over the past two years and the majority of the Company's reported R&D expenses are spent on selected early discovery projects.

4. Acquisitions and partnerships opening new routes of growth and innovation

Evotec also increasingly invests in developing early assets in highly innovative areas of drug discovery such as regenerative medicine (e.g. beta cell regeneration) and technologies to better understand oncology or metabolic diseases to support further growth. To this end the Company has executed two strategic acquisition processes in 2010 to kick-start novel innovative approaches in drug discovery.

In July 2010, Evotec acquired DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders. The transaction added expertise and early discovery assets in two key fields of high unmet medical needs, especially diabetes and metabolic disorders, and additionally opened the field of regenerative medicine - a key strategic step for Evotec in 2010.

The acquisition also augmented and complemented Evotec's high-end drug discovery platform and capability with DeveloGen's target discovery, validation and in vivo/in vitro pharmacology expertise and added core disease biology know-how in metabolic diseases. These skills further enhance Evotec's ability to deliver high quality, innovative solutions to its partners on a global scale.

In December 2010, Evotec entered into a license and collaboration agreement with MedImmune Ltd, a wholly owned subsidiary of AstraZeneca, in the field of diabetes with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research and development programmes and represents the first deal executed by Evotec on assets and capabilities acquired through its purchase of DeveloGen. After integration of Evotec Gottingen (formerly DeveloGen) the business is profitable and strongly growing.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,692.67 -58.72 -0.33%
S&P 500 2,098.95 -9.62 -0.46%
NASDAQ 5,087.2030 -24.53 -0.48%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs